nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.12.2009 | Original Paper

Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer

verfasst von: Ming-Huang Chen, Peter Mu-Hsin Chang, Po-Min Chen, Cheng-Hwai Tzeng, Pen-Yuan Chu, Shyue-Yih Chang, Muh-Hwa Yang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

The purpose of this retrospective study was to test whether the pretreatment hematologic profile can predict the prognosis of patients with head and neck cancer.

Methods

Medical records from 278 patients with head and neck cancer were reviewed, and 270 cases were evaluable. Clinical data including age, gender, stage, pretreatment hematologic profile (including white blood cell, platelet, and differential counts, and hemoglobin level) were recorded. Statistical analyses were performed to determine the prognostic effect of these hematologic indicators, as well as clinical variables. The association between the hematologic indicators and clinical factors was also analyzed.

Results

Pretreatment monocytes >1,000 cells/μl (P = 0.028), hemoglobin <11.0 g/dl (P = 0.022), and platelet count >400 × 10³ cells/μl (P = 0.017) were identified as independent prognostic factors in addition to the nodal status and metastasis. A significant correlation between T-stage/monocyte or platelet count and metastasis/platelet count were shown. Monocytosis, anemia, and thrombocytosis were demonstrated to have a cumulative effect on the prognosis of head and neck cancer patients (normal vs. abnormality in one lineage, P = 0.001; abnormality in one vs. more than one lineage, P = 0.005).

Conclusions

A pretreatment hematologic profile can be considered as a useful prognostic marker in patients with head and neck cancer.

Ahn GO, Brown JM (2008) Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13:193–205. doi:10.1016/j.ccr.2007.11.032 PubMedCrossRef

Baghi M, Wagenblast J, Hambek M, Moertel S, Gstoettner W, Strebhardt K, Knecht R (2008) Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients. Clin Otolaryngol 33:245–251. doi:10.1111/j.1749-4486.2008.01702.x PubMedCrossRef

Becker A, Stadler P, Lavey RS, Hänsgen G, Kuhnt T, Lautenschläger C, Feldmann HJ, Molls M, Dunst J (2000) Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 46:459–466. doi:10.1016/S0360-3016(99)00384-3 PubMedCrossRef

Brockmann MA, Giese A, Mueller K et al (2007) Preoperative thrombocytosis predicts poor survival in patients with glioblastoma. Neuro-oncol 9:335–342. doi:10.1215/15228517-2007-013 PubMedCrossRef

Caro JJ, Salas M, Ward A et al (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91:2214–2221. doi:10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P PubMedCrossRef

Chen CC, Chang JY, Liu KJ et al (2005) Hepatocellular carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis. Ann Oncol 16:988–989. doi:10.1093/annonc/mdi171 PubMedCrossRef

Cox DR (1972) Regression models and life tables. J R Stat Soc Ser 34:187–220

De Palma M, Venneri MA, Roca C et al (2003) Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9:789–795. doi:10.1038/nm871 PubMedCrossRef

Department of Health (2004) The Executive Yuan cancer registry annual report in Taiwan area. Department of Health, ExecutiveYuan, ROC

Dirkx AE, Oude Egbrink MG, Wagstaff J et al (2006) Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 80:1183–1196. doi:10.1189/jlb.0905495 PubMedCrossRef

Dunst J, Kuhnt T, Strauss HG et al (2003) Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 56:778–787. doi:10.1016/S0360-3016(03)00123-8 PubMed

Gogus C, Baltaci S, Filiz E et al (2004) Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 63:447–450. doi:10.1016/j.urology.2003.10.039 PubMedCrossRef

Greene FL, Leslie HS (2008) The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin 58:180–190. doi:10.3322/CA.2008.0001

Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New York

Hockel M, Schlenger K, Mitze M et al (1996) Hypoxia and radiation response in human tumors. Semin Radiat Oncol 6:3–9. doi:10.1016/S1053-4296(96)80031-2 PubMedCrossRef

Ikeda M, Furukawa H, Imamura H et al (2002) Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 9:287–291PubMedCrossRef

Kasuga I, Makino S, Kiyokawa H et al (2001) Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 92:2399–2405. doi:10.1002/1097-0142(20011101)92:9<2399::AID-CNCR1588>3.0.CO;2-W PubMedCrossRef

Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605–612. doi:10.1158/0008-5472.CAN-05-4005 PubMedCrossRef

Lu CC, Chang KW, Chou FC et al (2007) Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma. Oral Oncol 43:283–288. doi:10.1016/j.oraloncology.2006.03.010 PubMedCrossRef

Lyden D, Hattori K, Dias S et al (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194–1201. doi:10.1038/nm1101-1194 PubMedCrossRef

Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U et al (2007) Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin Chim Acta 380:208–212. doi:10.1016/j.cca.2007.02.037 PubMedCrossRef

Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156. doi:10.1002/ijc.1440 PubMedCrossRef

Patruno R, Arpaia N, Gadaleta CD et al (2008) VEGF concentration from plasma activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. J Cell Mol Med 13:555–561. doi:10.1111/j.1582-4934.2008.00355.x PubMedCrossRef

Pedersen LM, Milman N (1996) Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 9:1826–1830. doi:10.1183/09031936.96.09091826 PubMedCrossRef

Pedersen LM, Milman N (2003) Diagnostic significance of platelet count and other blood analyses in patients with lung cancer. Oncol Rep 10:213–216PubMed

Peto R, Pike MC (1973) Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics 29:579–584. doi:10.2307/2529177 PubMedCrossRef

Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71–78. doi:10.1038/nrc1256 PubMedCrossRef

Rades D, Schild SE, Bahrehmand R et al (2005) Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy: the importance of pretreatment hemoglobin levels. Cancer 103:1740–1746. doi:10.1002/cncr.20952 PubMedCrossRef

Rudat V, Dietz A, Schramm O et al (1999) Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol 53:119–125. doi:10.1016/S0167-8140(99)00119-X PubMedCrossRef

Shimada H, Oohira G, Okazumi S et al (2004) Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 198:737–741. doi:10.1016/j.jamcollsurg.2004.01.022 PubMedCrossRef

Sugitani I, Kasai N, Fujimoto Y et al (2001) Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 25:617–622. doi:10.1007/s002680020166 PubMedCrossRef

Suzuki K, Aiura K, Kitagou M et al (2004) Platelets counts closely correlate with the disease-free survival interval of pancreatic cancer patients. Hepatogastroenterology 51:847–853PubMed

Taucher S, Salat A, Gnant M et al (2003) Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost 89:1098–1106PubMed

Uemura Y, Kobayashi M, Nakata H et al (2006) Effects of GM-CSF and M-CSF on tumor progression of lung cancer: roles of MEK1/ERK and AKT/PKB pathways. Int J Mol Med 18:365–373PubMed

Van Belle SJ, Cocquyt V (2003) Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 47:1–11. doi:10.1016/S1040-8428(03)00093-3 PubMedCrossRef

Verheul HM, Jorna AS, Hoekman K et al (2000) Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96:4216–4221PubMed

Yang L, DeBusk LM, Fukuda K et al (2004) Expansion of myeloid immune suppressor Gr+ CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409–421. doi:10.1016/j.ccr.2004.08.031 PubMedCrossRef

Yang MH, Wu MZ, Chiou SH et al (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10:295–305. doi:10.1038/ncb1691 PubMedCrossRef

Titel: Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer
verfasst von: Ming-Huang Chen
Peter Mu-Hsin Chang
Po-Min Chen
Cheng-Hwai Tzeng
Pen-Yuan Chu
Shyue-Yih Chang
Muh-Hwa Yang
Publikationsdatum: 01.12.2009
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-009-0625-1

Springer Medizin

Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer